Avacta Group plc (formerly Readybuy plc)
First Day of Dealings on AIM
Avacta Group plc ("the Company") announces the re-admission of its existing
ordinary shares; the admission of 45,000,000 Placing Shares and the admission
of 475,530,102 new Ordinary Shares issued pursuant to the Acquisition Agreement
to trading on AIM today.
A total of 644,857,446 Ordinary Shares were admitted to trading, giving a
market capitalisation for the Company, at the placing price of 2.25p per share,
of £14.5m.
At the Extraordinary General Meeting of the Company held on Monday 7 August,
Daron Lee resigned as a director of the Company; Professor Alastair Smith was
appointed Chief Executive and Dr. Gwyn Humphreys, Dr. Simon Webster, Dr. Kurt
Baldwin, Tim Sykes, Professor Tony Robards OBE and Alan Aubrey were appointed
directors of the Company.
Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:
"I am delighted that this transaction, leading to our listing on AIM, is on
schedule and the funds raised will enable us to focus on the development of our
first products. Our relocation to the York Biocentre has been completed
successfully with a seamless transition of our laboratories and staff.
"Our focus is on delivering multiple revenue streams for shareholders through a
range of products and services designed to identify and rapidly analyse
substances at the molecular level. Such technology will initially be exploited
through applications within the defence, homeland security and
biopharmaceutical markets where the need exists for timely analysis of
chemicals, viruses, bacteria and proteins such as toxins and antibodies.
"We look forward to an exciting year of progress and anticipate regular
newsflow concerning product development and planned collaborative agreements"
8th August 2006
Enquiries:
Avacta Group plc Tel: 0870 835 4367
Alastair Smith, Chief Executive
WH Ireland Limited Tel: 0161 832 2174
David Youngman, Director, Corporate Finance
Nexus Financial Ltd Tel: 020 7451 7050
Nicholas Nelson, Director nicholas.nelson@nexusgroup.co.uk
In accordance with Schedule Two(g) of the AIM Rules, the Company is pleased to
provide the information below:-
Director Age Current directorships Previous directorships
(last five years)
Professor David 39 Avacta Limited Hebden Lodge Hotel
Alastair Maclaughlin Company Limited
Smith Avacta Analytical Limited
TT123 Limited
Dr. Simon Webster 38 Avacta Limited None
Avacta Analytical Limited
Dr. Kurt Justin 38 Avacta Limited None
Baldwin
Avacta Analytical Limited
Dr. Gwynfor Owen 60 Avacta Limited Bradford Particle Design
Humphreys Limited
Elucidos Limited
Nektar Therapeutics UK
Connect Yorkshire Limited
Inside track I LLP
Inside track II LLP
Syntopix Group plc
Syntopix Services Limited
Syntopix Limited
Bioniqs Limited
Professor Anthony 66 Avacta Limited Bioincubator York Limited
William Robards
Yorkshire Cancer Research Business Link York and
Limited North Yorkshire Limited
York and North Yorkshire Knowledge Base (UK)
Limited
Inward Investment Board
Limited Yhman Limited
Yorktest Laboratories Yorkshire Building
Limited Society Charitable
Foundation
York Science Park
(Innovation Centre) York and North Yorkshire
Limited Chamber of Commerce
York Science Park Limited White Rose Research
Limited
York Professional
Initiative
Yorktest Group Limited
Pro-Cure Therapeutics
Limited
Venturefest (York) Limited
Connect Yorkshire
LG01 Limited
Elucidos Limited
Alan John Aubrey 45 Aquarius Equity Partners AXM Venture Capital
Limited Limited
Axiomlab Empiricom Technologies
Limited
Axiomlab Limited
Energetix Group Limited
Axiomlab Group plc
Flexisols Limited
Axiomlab Investment
Management Limited NWSF Holdings Limited
Axiomlab Investments Thermetica Limited
Limited
Inhoco 2835 Limited
Inhoco 2895 Limited
IP Group Plc
Life UK (IP21PO) Limited
Modern Biosciences Plc
PROACTIS Group Limited
PROACTIS Holdings PLC
Syntopix Group Plc
Syntopix Limited
Techtran Corporate Finance
Limited
Techtran Group Limited
Techtran Investments
Limited
Techtran Limited
Techtran Services Limited
IP2IPO Limited
IP2IPO Management Limited
IP2IPO Management II
Limited
IP Venture Fund (GP)
Limited
IP Ventures (Scotland)
Limited
HATT III General Partner
Limited
Top Technology Ventures
Limited
TTV IV G.P. Limited
Timothy James Sykes 36 Avacta Limited Mountain Warehouse
Limited
Avacta Analytical Limited
Mountain Warehouse
Penta Financial Direction Holdings Limited
Limited
PROACTIS Group Limited
PROACTIS Holdings PLC
There are no other disclosures required under Schedule Two (g).
All terms used in this announcement are defined as set out in the Admission
Document dated 13 July 2006.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.